ResearchMoz presents professional and in-depth study of "Behavioral Disorders Drug Development Pipeline Review, 2017".
This report provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.
Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1343221
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include childs sex, family history, fragile X syndrome, Tourette syndrome and epilepsy.
Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again.
Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities.
The size of these pipelines ranges from 8 products in obsessive-compulsive disorder to 58 products in attention deficit hyperactivity disorder. Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.
Scope
- Which companies are the most active within the pipeline for behavioral disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1343221
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
This report provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.
Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1343221
Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include childs sex, family history, fragile X syndrome, Tourette syndrome and epilepsy.
Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again.
Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities.
The size of these pipelines ranges from 8 products in obsessive-compulsive disorder to 58 products in attention deficit hyperactivity disorder. Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.
Scope
- Which companies are the most active within the pipeline for behavioral disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1343221
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment